United States: 5 Health Care Policy Issues To Follow In 2018

We hope you recharged over the holidays, because we expect health care policy to remain at the forefront as the 115th Congress enters its second session. Both chambers returned on Wednesday after which they will have a scheduled 108 days in the U.S. House of Representatives and 156 days in the U.S. Senate before the mid-term elections. While congressional Republicans safely hold the majority, we anticipate strong efforts to advance their legislative agenda.

Here are the top five health care policy issues to watch for in 2018:

Affordable Care Act "Repeal and Replace"

Expect Congress to make at least one last push to repeal the Affordable Care Act. While Republicans made strides in 2017, they have not fully delivered on their campaign trail promise to "repeal and replace" the ACA.

Congress ended the year by repealing the individual mandate, a central element of the ACA. Under the Tax Cuts and Jobs Act (TCJA), starting in 2019, the penalty for an individual's failure to maintain minimum essential coverage will be reduced to zero. House Speaker Paul Ryan, R-Wis., has vowed to continue pursuing full-scale repeal in 2018, as many of the conference's key priorities remain.

In addition to ACA repeal, we anticipate that Congress will consider legislation that would stabilize the ACA individual marketplace early in 2018. Sen. Susan Collins, R-Maine, had conditioned her vote on the TCJA on passage of two market stabilization bills – the Bipartisan Health Care Stabilization Act and the Federal Reinsurance Act – before the end of 2017. Given the tight timeline and a potential government shutdown right before Christmas, she agreed to push the measures to January.

It is likely, however, that health care reform will face similar challenges as experienced this year, including partisan tensions and intraparty disagreements. Further complicating efforts is Republicans' narrowed majority, with Sen. Doug Jones, D-Ala., replacing Sen. Luther Strange, R-Ala., in the chamber. Even if leadership chooses, once again, to pursue reforms through budget reconciliation – which requires 50 votes in the Senate (as opposed to 60) – Senate Republicans will be able to afford only one defection.

Entitlement Reform

Another contender for budget reconciliation is entitlement reform, which Ryan has indicated that he plans to pursue in 2018. The Medicaid program, which is projected to account for approximately $385 billion of federal spending in 2017, will be a prime target.1

We expect to see policies aimed at controlling federal spending and shifting authority from the federal government to the states. Proposals will likely be similar to those included in the House-passed American Health Care Act and other ACA repeal and replace measures, such as phasing down Medicaid expansion, as well as shifting Medicaid financing from a federal-state match to a state block grant or per capita allotment.

Prescription Drug Pricing

The rising cost of prescription drugs has intensified, drawing attention and fire across the political spectrum and in the media. This year, legislators introduced over 25 bills and several congressional health care and oversight committees held hearings to investigate the issue. We expect that congressional attention on this issue will continue in 2018.

While the parties have generally not been aligned on drug pricing reforms, proposals aimed at increasing competition have attracted bipartisan interest. The U.S. Food and Drug Administration Reauthorization Act of 2017, which nearly unanimously passed both chambers, codified an expedited pathway for certain generics if the secretary determines that there is "inadequate generic competition." Additionally, during a recent Senate Health, Education, Labor, and Pensions Committee hearing, bipartisan members voiced support for addressing anti-competitive practices in bringing generics and biosimilars to the market, as well as prohibiting pay-for-delay agreements.

340B Drug Pricing Program

2018 could be the year that Congress enacts reforms to the 340B Drug Pricing Program. Over the past several years, the 340B program has been marked by considerable uncertainty, driven, in part, by tension over the intent of the program and debate over the Health Resources and Services Administration's (HRSA) oversight and regulatory authority over the program.

The House Energy & Commerce Committee has taken the lead on 340B reform, with its Oversight Subcommittee expected to release a report on 340B early next year. Committee members, Reps. Chris Collins, R-N.Y., and Buddy Carter, R-Ga., have been developing comprehensive 340B reform legislation, which could codify many unresolved issues, including the scope of HRSA's oversight and regulatory authority, the definition of a "patient," and the original intent of the 340B program.

More immediately, if not addressed before the end of this year, we anticipate efforts to roll back CMS's 2018 outpatient prospective payment system (OPPS) final rule, which starting on Jan. 1, 2018, will reduce reimbursement for certain separately payable, non-pass through Part B drugs purchased under the 340B program. Legislation, which would block implementation of the Medicare payment cuts for drugs purchased under the 340B program, has strong bipartisan support. 2


Rates of opioid misuse and addiction continue to skyrocket, with the National Institute on Drug Abuse (NIDA) estimating that over 91 Americans die from an opioid overdose each day. 3 The White House declared the opioid epidemic a national emergency in October, and there is broad agreement among policymakers that increased funding and policy solutions are needed.

Two signature achievements of the 114th Congress – the Comprehensive Addiction and Recovery Act (CARA) of 2016 and the 21st Century Cures Act – authorized federal grants to states to supplement opioid abuse prevention and treatment activities, including improving prescription drug monitoring, training for health care providers, and expanding access to opioid treatment programs. The 21st Century Cures Act provided funding authorization for such programs during the 2017 and 2018 fiscal years.

Senate Health, Education, Labor, and Pensions (HELP) Committee Chair Lamar Alexander, R-Tenn., has called for additional funding, though it remains unclear how much Congress will authorize and appropriate. In addition to funding, we expect lawmakers to explore policy solutions, which could include requiring health care providers who prescribe opioids to complete continuing education, expanding the Drug Enforcement Administration's enforcement authority, and strengthening requirements for state prescription drug monitoring programs.

Potential Legislative Vehicles

There will be no shortage of legislative vehicles for these policies, as several federal health care programs will be up for reauthorization next year. Programs set to expire at the end of the 2018 fiscal year include:

Pandemic and All-Hazards Preparedness Act

Legal authorities designed to prepare the United States and health professionals for pandemic, epidemic or biological, chemical, radiological, or nuclear accidents and attacks are set to expire at the end of fiscal year 2018. The Pandemic and All-Hazards Preparedness Reauthorization Act of 2013 improved the nation's preparedness for public health emergencies. However, our vulnerability to natural and intentional public health threats remains high, as evidenced by the Ebola and Zika outbreaks and reports of enhanced biological weapon capabilities by state actors such as North Korea, combined with the challenge of increased antimicrobial resistance. Congress will need to turn to funding for medical countermeasures such as vaccines, drugs, therapies and diagnostic tools necessary to address public health emergencies and programs that protect Americans and the global community from health security threats.

President's Emergency Plan for AIDS Relief

The creation of the president's Emergency Plan for AIDS Relief (PEPFAR) in 2003 was a landmark in bipartisan congressional commitment to combatting the global HIV/AIDS, tuberculosis and malaria epidemics. Congress reauthorized the program with bipartisan support in 2008 and 2013. PEPFAR funding constitutes the bulk of U.S. global health funding of global health programs and reflects the largest commitment by any nation to address a single disease in the world. The current strategy aligns with the United Nation's AIDS framework, focuses on reducing HIV infections among adolescent girls and young women in 10 sub-Saharan African countries, and emphasizes accelerating testing and treatment strategies, expanding prevention, engaging with faith-based organizations and the private sector, and strengthening policy and financial contributions by partner countries. Program authorities expire at the end of this fiscal year.

Health Care Workforce Programs

Several key health care workforce programs administered by the Health Resources and Services Administration under the Public Health Service Act have expired, and are likely to be reauthorized in 2018. These include health professions and nursing workforce development programs, the Children's Health Graduate Medical Education program, and the Teaching Health Center Graduate Medical Education programs. These programs have traditionally enjoyed bipartisan support in both chambers.

We hope you got some rest, 2018 is sure to be a busy year for health care attorneys.

Originally published in Law360


1. Projections for Major Health Care Programs for 2017, Congressional Budget Office (last updated June 2017). Available at: https://www.cbo.gov/topics/health-care.

2. H.R. 4392, To provide that the provision of the Medicare Program: Hospital Outpatient Prospective Payment and Ambulatory Surgical Center Payment Systems and Quality Reporting Programs final regulation relating to changes in the payment amount for certain drugs and biologicals purchased under the 340B drug discount program shall have no force or effect, and for other purposes.

3. Opioid Overdose Crisis, National Institute on Drug Abuse (revised June 2017).

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on Mondaq.com.

Click to Login as an existing user or Register so you can print this article.

In association with
Related Video
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:
  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.
  • Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.
    If you do not want us to provide your name and email address you may opt out by clicking here
    If you do not wish to receive any future announcements of products and services offered by Mondaq you may opt out by clicking here

    Terms & Conditions and Privacy Statement

    Mondaq.com (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

    Use of www.mondaq.com

    You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about Mondaq.com’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


    Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

    The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


    Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

    • To allow you to personalize the Mondaq websites you are visiting.
    • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
    • To produce demographic feedback for our information providers who provide information free for your use.

    Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

    Information Collection and Use

    We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

    We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to unsubscribe@mondaq.com with “no disclosure” in the subject heading

    Mondaq News Alerts

    In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


    A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

    Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

    Log Files

    We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


    This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

    Surveys & Contests

    From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


    If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


    From time to time Mondaq may send you emails promoting Mondaq services including new services. You may opt out of receiving such emails by clicking below.

    *** If you do not wish to receive any future announcements of services offered by Mondaq you may opt out by clicking here .


    This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to webmaster@mondaq.com.

    Correcting/Updating Personal Information

    If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to EditorialAdvisor@mondaq.com.

    Notification of Changes

    If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

    How to contact Mondaq

    You can contact us with comments or queries at enquiries@mondaq.com.

    If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at problems@mondaq.com and we will use commercially reasonable efforts to determine and correct the problem promptly.

    By clicking Register you state you have read and agree to our Terms and Conditions